REDWOOD CITY, Calif.,
Nov. 29, 2016 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it
will present seven Oncotype DX® studies at the
39th CTRC-AACR San Antonio Breast Cancer Symposium
(SABCS), which is being held December 6-10,
2016. The study findings reinforce the Company's leadership
in individualizing breast cancer treatment decisions and the value
of the Oncotype DX test in various stages of the disease.
Presentations include:
- Results from a study based on the Surveillance, Epidemiology,
and End Results (SEER) registry program of the National Cancer
Institute (NCI), the premier source of cancer statistics in
the United States. The study
assessed breast cancer-specific mortality in patients with poorly
differentiated tumors who were treated based on their Oncotype DX
Breast Recurrence Score™ results.
- A gene discovery study conducted in collaboration with SWOG, an
NCI cooperative group, that analyzed molecular predictors of early
breast cancer outcomes, highlighting Genomic Health's leadership in
using next-generation sequencing for gene expression analysis.
- A comparison of the use of commonly available clinical
predictive tools and physician estimates vs. the Oncotype DX Breast
DCIS Score™ to determine ipsilateral breast event risks in patients
with ductal carcinoma in situ (DCIS) post-lumpectomy.
- A study design for an ongoing study evaluating the use of the
Breast Recurrence Score results in patients with metastatic breast
cancer at the time of first diagnosis.
- A summary of the unprecedented amount of clinical outcomes
evidence from more than 50,000 patients across multiple large
studies.
- A multi-center trial evaluating the use of Oncotype DX to
select neoadjuvant therapy for early-stage breast cancer.
- A decision impact study demonstrating the value of using
Oncotype DX in eligible patients in France.
Complete results from the studies will be announced in
accordance with the SABCS embargo policy. Following are details for
each presentation (all times are in Central Standard Time):
Wednesday, December
7
- Abstract: P1-11-02
Poster: "A comparison of models (physician, the Van Nuys prognostic index, the
Memorial-Sloan-Kettering Cancer Center DCIS nomogram) to predict
ipsilateral breast events in patients with ductal carcinoma in situ
(DCIS) of the breast after breast-conserving surgery failed to
replicate results of the oncotype DCIS recurrence score"
Authors: Leonard C, Lei R, Antell A, Nowels M, Fryman S, Howell K,
Dennis C.
Location: Hall 1
Time: 5 – 7 p.m.
Thursday, December 8
- Abstract: P2-10-04
Poster: "Using the 21-gene assay from core needle biopsies to
choose neoadjuvant therapy for breast cancer: A multicenter
trial"
Authors: Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White,
Jr. RL, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing
AP.
Location: Hall 1
Time: 7:30 – 9 a.m.
Friday, December 9
- Abstract: PD7-06
Poster Discussion: "SEER study of breast cancer-specific mortality
in patients with poorly differentiated tumors treated based on
Recurrence Score results"
Authors: Petkov VI, Miller DP, Howlader N, Baehner FL, Penberthy L,
Shak S.
Location: Stars at Night Ballroom 1 and 2 (Level 3)
Time: 7:30 – 9 a.m.
- Abstract: PD7-07
Poster Discussion: "Discovery of molecular predictors of late
breast cancer specific events (BCSE) in ER+, node+ breast cancer –
new transcriptome expression whole gene analysis of the phase III
adjuvant trial SWOG S8814"
Authors: Albain KS, Crager MR, Barlow
WE, Baehner FL, Bergamaschi A, Rae JM, Ravdin PM, Tripathy
D, Gralow JR, Livingston RB, Osborne CK, Ingle JN, Pritchard KI,
Davidson NE, Carey LA, Cherbavaz DB, Sing AP, Shak S, Hortobagyi
GN, Hayes DF.
Location: Stars at Night Ballroom 1 and 2 (Level 3)
Time: 7:30 – 9 a.m.
- Abstract: OT3-04-04
Poster: "21-gene recurrence score® in patients with primary
metastatic ER+ HER2- breast cancer"
Authors: Barinoff J, Anastasiadou L, Brandi C, Junker-Stein A,
Silbermann J, Langenfeld M, Fortmann C, Thill M.
Location: Hall 1
Time: 5 – 7 p.m.
Saturday, December 10
- Abstract: P6-09-08
Poster: "Real-world clinical experience and outcomes in patients
with early-stage breast cancer (EBC) treated according to the
21-gene Recurrence Score® (RS) result"
Authors: Sing AP, Rothney M, Svedman C, Shak S, Baehner FL.
Location: Hall 1
Time: 7:30 – 9 a.m.
- Abstract: P6-07-28
Poster: "The 21-gene assay in the decision impact assessment of
ER+, HER2- breast cancer: A French real life prospective study"
Authors: Gligorov J, Dohollou N, Mouysset JL, Laplaige P, Fignon A,
Lafuma A, Michaud P. Location: Hall 1
Time: 7:30 – 9 a.m.
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions. The
company's flagship product, the Oncotype DX breast cancer test, has
been shown to predict the likelihood of chemotherapy benefit as
well as recurrence in invasive breast cancer. Additionally, the
test predicts the likelihood of recurrence in a pre-invasive form
of breast cancer called DCIS. With more than 700,000 patients
tested in more than 90 countries, the Oncotype DX tests have
redefined personalized medicine by making genomics a critical part
of cancer diagnosis and treatment. To learn more
about Oncotype DX tests, visit www.OncotypeDX.com or
www.MyBreastCancerTreatment.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care by addressing the
overtreatment of the disease, one of the greatest issues in
healthcare today. With its Oncotype IQ™ Genomic
Intelligence Platform, the company is applying its world-class
scientific and commercial expertise and infrastructure to lead the
translation of clinical and genomic big data into actionable
results for treatment planning throughout the cancer patient
journey, from diagnosis to treatment selection and monitoring. The
Oncotype IQ portfolio of genomic tests and services currently
consists of the company's flagship line of Oncotype DX gene
expression tests that have been used to guide treatment decisions
for more than 700,000 cancer patients worldwide. Genomic
Health is expanding its test portfolio to include additional
liquid- and tissue-based tests, including the recently launched
Oncotype SEQ® Liquid Select assay. The company is based
in Redwood City, California, with international
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and the other risks set forth in the company's filings with
the Securities and Exchange Commission, including the risks
set forth in the company's quarterly report on Form 10-Q for the
quarter ended September 30, 2016. These forward-looking
statements speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are
trademarks or registered trademarks of Genomic Health,
Inc. All other trademarks and service marks are the property
of their respective owners.
GHDX-B
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-announces-presentation-of-multiple-oncotype-dx-studies-at-the-2016-ctrc-aacr-san-antonio-breast-cancer-symposium-reinforcing-value-of-genomics-in-precision-medicine-300369255.html
SOURCE Genomic Health, Inc.